BigHat Biosciences CEO Peyton Greenside criticized hype around AI drug discovery, arguing that demonstrations showing rapid molecule design miss the downstream work required to make therapies. In the STAT+ segment, Greenside said her team can design proteins quickly—she cited 20 minutes in-house—but stressed that validation, testing, and manufacturing remain the “hard work.” The company highlighted completed collaboration work with Johnson & Johnson and existing partnerships with Merck, Amgen, AbbVie, and others. Greenside’s comments position BigHat’s messaging around translating design speed into rigorous experimental and development timelines. The pushback matters for biotech investors and partners evaluating AI platforms, because the business case increasingly depends on execution metrics beyond algorithmic throughput.